fbpx

Multiple Myeloma Knowledge Hub

Risk Factors and Incidence of Acute Kidney Injury in Patients Receiving CAR-T Cell Therapy

Chimeric antigen receptor (CAR) T-cell therapy is a major advancement in the personalized treatment of hematological malignancies, and it is being explored in the...

The Role of Medical Imaging in Managing Patients Receiving CAR T-Cell Therapy

Chimeric antigen receptor (CAR) T-cell therapy has provided a novel, effective treatment option for patients with relapsed or refractory non-Hodgkin lymphoma. However, many patients...
blurred figures of doctors and nurses in a hospital corridor

Study Identifies Cytokines Potentially Involved in Neurotoxicity Syndrome After CAR T-Cell Therapy

Chimeric antigen receptor (CAR) T-cell therapy is a promising new option for treatment of hematologic malignancies, but many patients who receive CAR T-cell therapy...

Recent Review Shows Promising Future for CAR T-Cell Therapy in Lung Cancer Treatment

Early research did not show that chimeric antigen receptor (CAR) T-cell therapy is effective against lung cancer, a solid tumor, despite its effectiveness in...

Hem/Onc Roundup: PSMA/PET Imaging in Prostate Cancer, Plus New FDA Approval for MM

This week on DocWire, editors spoke with Dr. Stefano Fanti, from the University of Bologna, Italy, about the critical role of PSMA-PET imaging in...
image of a newspaper

Response to COVID-19 Vaccine Variable in Multiple Myeloma Patients

Patients with multiple myeloma (MM) mount a highly variable antibody response after receipt of a two-dose mRNA COVID-19 vaccination regimen, according to a study...

Researchers Encourage Exploration of Dual-Targeted CAR T-Cell Treatment in Multiple Myeloma

Targeted immunotherapy is a very promising strategy in the treatment of multiple myeloma (MM). Specifically, clinical trials using chimeric antigen receptor (CAR) T-cells to...
Advertisement

Journal Reading List

Advertisement
Advertisement